Results 81 to 90 of about 85,640 (310)

Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects [PDF]

, 2007
Cryoglobulinaemia may cause cutaneous vasculitis and glomerulonephritis, potentially leading to end stage renal failure. An important proportion of cryoglobulinaemias are secondary to hepatitis C virus infection.
Braun, Gerald S., Horster, Sophia, Ihrler, Stephan, Schmid, Holger, Wagner, Katrin S.   +4 more
core   +2 more sources

Immunological Profiling suggests an Association between Treg dysfunction and Pain in Knee Osteoarthritis

Arthritis &Rheumatology, Accepted Article.
Background Pain is the hallmark symptom of osteoarthritis (OA) and its biological drivers remain poorly understood. While the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular regulatory T cells (Tregs), is not well understood. Methods We performed omics profiling of peripheral blood from 46
Marie Binvignat, Johanna Dubois, Maria Marco Salvador, Paul Stys, Fabien Pitoiset, Alexandra Roux, Michèle Sastre, Signe Hassler, Roberta Lorenzon, Claire Ribet, Vanessa Mhanna, Hélène Vantomme, Leslie Adda, Pierre Barennes, Nicolas Coatnoan, Kenz Le Gouge, Caroline Aheng, Alice Courties, Lise Minssen, Atul J. Butte, Adrien Six, Michelle Rosenzwajg, Nicolas Tchitchek, Francis Berenbaum, David Klatzmann, Encarnita Mariotti‐Ferrandiz, Jérémie Sellam   +26 more
wiley   +1 more source

Decision tree analysis as a preliminary evidence‐based tool for identifying the syndrome of undifferentiated recurrent fever in children compared with hereditary recurrent fevers and periodic fever, aphthosis, pharyngitis and adenitis syndrome

Arthritis &Rheumatology, Accepted Article.
Objective To develop evidence‐based criteria to classify SURF patients. Methods 112 SURF patients followed in a single tertiary referral center were analyzed. Patients with genetically confirmed hereditary recurrent fever (HRF) or with periodic fever, aphthosis, pharyngitis and adenitis (PFAPA) syndrome already analyzed for the Eurofever classification
Riccardo Papa, Francesca Bovis, Silvia Federici, Serena Palmeri, Marta Bustaffa, Giada Recchi, Roberta Bertelli, Roberta Caorsi, Stefano Volpi, Sabrina Fuehner, Veysel Cam, Anna Kozáková, Šárka Horáčková Fingerhutová, Antonella Insalaco, Dirk Foell, Seza Ozen, Isabella Ceccherini, Marco Gattorno, on behalf of the Eurofever study group for the Classification criteria of recurrent fevers and PerSAID project, Michael Hofer, Federica Vanoni, Jordi Anton, Juan Ignacio Arostegui, Karyl S. Barron, Eldad Ben‐Chetrit, Paul Brogan, Luca Cantarini, Isabella Ceccherini, Fabrizio De Benedetti, Fatma Dedeoglu, Erkan Demirkaya, Joost Frenke, Raphaela Goldbach‐Mansky, Ahmet Gul, Veronique Hentgen, Hal M. Hoffman, Tilmann Kallinich, Isabelle Koné‐Paut, Jasmin Kuemmerle‐Deschner, Helen J. Lachmann, Ronald M. Laxer, Avi Livneh, Laura Obici, Dorota Rowczenio, Ricardo Russo, Yael Shinar, Anna Simon, Natasa Toplak, Isabelle Touitou, Yosef Uziel, Marielle van Gijn, Daniel L. Kastner, Alberto Martini, Maria Pia Sormani, Nicolino Ruperto   +54 more
wiley   +1 more source

Post-COVID arthralgia

Indian Journal of Rheumatology, 2022
Ganesh Singh Dharmshaktu
doaj   +1 more source

A Telehealth-Delivered Tai Chi Intervention (TaiChi4Joint) for Managing Aromatase Inhibitor–Induced Arthralgia in Patients With Breast Cancer During COVID-19: Longitudinal Pilot Study [PDF]

, 2022
Sameh Gomaa, Carly West, Ana Mariá López, Tingting Zhan, Max Schnoll, Maysa Abu‐Khalaf, Andrew B. Newberg, Kuang‐Yi Wen   +7 more
openalex   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source

Shoulder arthralgia: case study of the Occupational Medicine clinic of Universidade Estadual de Campinas (Unicamp) [PDF]

, 2022
William Prado, Valmir Azevedo, Sérgio Roberto de Lucca, Márcia Bandini   +3 more
openalex   +1 more source

Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age [PDF]

, 2017
Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1.
Giovanni Corsello, Luca Cantarini, Maria Cristina Maggio, Rolando Cimaz, Umberto Corpora   +4 more
core  

Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases [PDF]

, 2016
Antibodies against carbamylated proteins (anti-CarP) have been recently identified in the sera of patients with rheumatoid arthritis (RA). The objective of the study was to evaluate the prevalence, sensitivity and specificity of anti-CarP compared to ...
Alessandri, Cristiano, Barbati, Cristiana, Ceccarelli, Fulvia, Colasanti, Tania, Conti, Fabrizio, DI FRANCO, Manuela, Mancini, Riccardo, Morello, Francesca, Pecani, Arbi, Pendolino, Monica, Priori, Roberta, Riccieri, Valeria, Sabatinelli, Danilo, Spinelli, FRANCESCA ROMANA, Truglia, Simona, Valesini, Guido, Vomero, Marta   +16 more
core   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source